Issue 2, 2020

De novo design of thioredoxin reductase-targeted heterometallic titanocene–gold compounds of chlorambucil for mechanistic insights into renal cancer

Abstract

Here we report the design and synthesis of a chlorambucil-alkynyl (CHL-CCH) ligand, mononuclear gold(I) complex K[(CHL-CC)AuCl], 1, and heteronuclear complex (CHL-CC)Au(μ22-CS3)Ti(η5-Cp)2, 2 for renal cancer. Complex 2 is significantly more cytotoxic than complex 1 and cisplatin against renal cancer cells with a high selectivity index value. The mechanism of action of these complexes against renal cancer cells was studied in detail by experimental and computational methods.

Graphical abstract: De novo design of thioredoxin reductase-targeted heterometallic titanocene–gold compounds of chlorambucil for mechanistic insights into renal cancer

Supplementary files

Article information

Article type
Communication
Submitted
20 Sep 2019
Accepted
29 Nov 2019
First published
30 Nov 2019

Chem. Commun., 2020,56, 297-300

De novo design of thioredoxin reductase-targeted heterometallic titanocene–gold compounds of chlorambucil for mechanistic insights into renal cancer

L. Tabrizi, L. O. Olasunkanmi and O. A. Fadare, Chem. Commun., 2020, 56, 297 DOI: 10.1039/C9CC07406F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements